The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 19 , ISSUE 7 ( 2018 ) > List of Articles

ORIGINAL RESEARCH

Prognostic Implication of Selective Serotonin Reuptake Inhibitors in Osseointegration of Dental Implants: A 5-year Retrospective Study

V Deepa, Karishma Mujawar, Komal Dhillon, Premraj Jadhav, Indrani Das, Youginder K Singla

Keywords : Dental implants, Selective serotonin reuptake inhibitors, Smokers

Citation Information : Deepa V, Mujawar K, Dhillon K, Jadhav P, Das I, Singla YK. Prognostic Implication of Selective Serotonin Reuptake Inhibitors in Osseointegration of Dental Implants: A 5-year Retrospective Study. J Contemp Dent Pract 2018; 19 (7):842-846.

DOI: 10.5005/jp-journals-10024-2345

License: CC BY-NC 3.0

Published Online: 00-07-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim: Dental implants are the preferred treatment modality in the present edentulous era. Selective serotonin reuptake inhibitors (SSRIs) have detrimental effect on bone density. The present study was conducted to determine the effect of SSRIs on the success rate of dental implants. Materials and methods: The present study was conducted on 352 patients of both genders with 680 dental implants. History of depression and SSRI medication was retrieved. Patients were divided into two groups. Group I (110 patients, 230 dental implants) patients were on SSRI, while group II (242 patients, 450 dental implants) patients were non-SSRI. In all patients, the implant failure rate was recorded. Results: In group I, 35 patients were >50 years, while 75 were <50 years of age. In group II, 60 patients were >50 years, while 182 were <50 years of age. The difference was significant (p < 0.05). Group I had 45 males and 65 females, while group II comprised of 105 males and 137 females. Group I showed 25 implant failures and group II had 21 implant failures. Age group >50 years showed 12 implant failures while <50 years had 13 in group I compared with 10 in patients >50 years and 11 in patients with <50 years of age; 56% smokers had implant in group I as compared with 60% failure in group II. In group I, 27% diabetic patients had failures as compared with 13.4% in group II. The difference was significant (p < 0.05). Group I showed maximum failures in terms of loosening of screw (8) followed by fracture of implant (7), peri-implantitis (6), and fracture of screw (4), whereas in group II, 7 cases were of loosening of screw, 6 cases were of fracture of screw, 5 cases of fracture of implant, and 3 cases of peri-implantitis. The difference was nonsignificant (p > 0.05). Conclusion: Selective serotonin reuptake inhibitors cause increased osteoclastic activity, leading to bone loss and implants placed in patients with history of depression are more prone to failures. Clinical significance: Failure rates of dental implants are significantly increased in patients taking SSRIs due to depression. Careful case analysis and history of depression may minimize the failure rates.


PDF Share
  1. Lang NP, Zitzmann NU; Working Group 3 of the VIII European Workshop on Periodontology. Clinical research in implant dentistry: evaluation of implant-supported restorations, aesthetic and patient-reported outcomes. J Clin Periodontol 2012 Feb;2(Suppl 12):133-138.
  2. Nisapakultorn K, Suphanantachat S, Silkosessak O, Rattanamongkolgul S. Factors affecting soft tissue level around anterior maxillary single-tooth implants. Clin Oral Implants Res 2010 Jun;21(6):662-670.
  3. Roos J, Sennerby L, Lekholm U, Jemt T, Grondahl K, Albrektsson T. A qualitative and quantitative method for evaluating implant success: a 5-year retrospective analysis of the Brånemark implant. Int J Oral Maxillofac Implants 1997 Jul-Aug;12(4):504-514.
  4. Bruyère O, Reginster JY. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine 2015 Feb;48(1):65-68.
  5. Nallaswamy VD, Karthikeyan R, Vinaya B. New Delhi, India: Jaypee Brothers Medical Publishing Lt; 2003. Textbook of Prosthodontics; pp. 720-730
  6. Fernandes BS, Hodge JM, Pasco JA, Berk M, Williams LJ. Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression. Drugs Aging 2016 Jan;33(1):21-25.
  7. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008 Oct;455(7215):894-902.
  8. Tsapakis EM, Gamie Z, Tran G, Adshead S, Lampard A, Mantalaris A, Tsiridis E. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2012 Apr;27(3):156-169.
  9. Wu X, Al-Abedalla K, Rastikerdar E, Abi Nader S, Daniel NG, Nicolau B, Tamimi F. Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failures: a cohort study. J Dent Res 2014 Nov;93(11):1054-1061.
  10. Charcanovic BR, Kisch J, Albrektsson T, Wennerberg A. Is the intake of selective serotonin reuptake inhibitors associated with an increased risk of dental implant failure? Int J Oral Maxifacial Surg 2017 Jun;46(6):782-788.
  11. Alsaadi G, Quirynen M, Komárek A, van Steenberghe. Impact of local and systemic factors on the incidence of late oral implant loss. Clin Oral Implants Res 2008 Jul;19(7): 670-676.
  12. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J Bone Miner Res 1991 Apr;6(4): 331-338.
  13. Negri M, Galli C, Smerieri A, Macaluso GM, Manfredi E, Ghiacci G, Toffoli A, Bonanini M, Lumetti S. The effect of age, gender, and insertion site on marginal bone loss around endosseous implants: results from a 3-year trial with premium implant system. BioMed Res Int 2014 Aug;2014:369051.
  14. Prakash PS, Victor DJ. Influence of diabetes on dental implants: a retrospective study. J Dent Implant 2012 Oct;2(2): 83-87.
  15. Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004 Sep;19(9): 1420-1431.
  16. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007 Jun;167(12):1240-1245.
  17. Noda K, Arakawa H, Kimura-Ono A, Yamazaki S, Hara ES, Sonoyama W, Maekawa K, Okura K, Shintani A, Matsuka Y, et al. A longitudinal retrospective study of the analysis of the risk factors of implant failure by the application of generalized estimating equations. J Prosthodont Res 2015 Jul;59(3):174-184.
  18. Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003;2:CD003592.
  19. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009 Jul;3:CD007954.
  20. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 2008 Feb;5(2):e45.
  21. Eom CS, Lee HK, Ye S, Park SM, Cho KH. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012 May;27(5):1186-1195.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.